HUTCHINSON, Minn.--(BUSINESS WIRE)--July 20, 2006--Hutchinson Technology Incorporated (Nasdaq:HTCH - News) announced today that it has received clearance from the U.S. Food and Drug Administration (FDA) to begin marketing its InSpectra(TM) StO2 Tissue Oxygenation Monitor. The patented device uses near infrared technology to noninvasively provide an absolute measurement of local tissue oxygen saturation (StO2). The InSpectra StO2 System is the only such device designed for clinical use in the trauma and emergency medicine settings.
